2024 World Conference on Lung Cancer (WCLC) - Posters-P2.17A.02 Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-bvzr in Metastatic Non-Small Cell Lung Cancer in Medicare

P2.17A.02 Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-bvzr in Metastatic Non-Small Cell Lung Cancer in Medicare

Back to course

Pdf Summary

The study explores the cost-efficiency of switching treatment for Medicare patients with metastatic non-small cell lung cancer (mNSCLC) from the original Bevacizumab (Avastin) to biosimilars, specifically Bevacizumab-bvzr (Zirabev). Utilizing a Microsoft Excel-based simulation model, the researchers evaluated potential savings within the context of Medicare, where 11% of diagnosed patients receive a Bevacizumab-based treatment.<br /><br />The analysis assumes 50% and 100% conversion scenarios to biosimilars. Results indicate that the mean per-patient-per-month (PPPM) savings are $4,205 for 50% conversion and $8,410 for 100% conversion. This represents a cost reduction of 35% and 70%, respectively, compared to treatment with the originator Bevacizumab. Total monthly savings for the patient cohort are $16,374,114 at 50% conversion and $32,748,228 at 100%.<br /><br />The study highlights the ability to reinvest these savings to treat more patients or cover other Medicare expenses in a budget-neutral manner. The research underscores that a complete switch to Bevacizumab-bvzr and other biosimilars not only generates significant cost savings but could also increase treatment access. <br /><br />Strengths of the study include its use of current cost measures and comprehensive assessment of available biosimilars. However, limitations are noted, including potential real-world variation in biosimilar uptake and treatment costs' central focus, which may overlook other therapeutic differences. The research emphasizes the need for continued evaluation as average sales prices change or new biosimilars enter the market.<br /><br />Overall, switching to biosimilar Bevacizumab-bvzr appears financially advantageous, promoting broader access without additional financial burden on Medicare.

Asset Subtitle

Joshua Roth

Meta Tag

Speaker Joshua Roth

Topic Global Health, Health Services & Health Economics

Keywords

Medicare

metastatic non-small cell lung cancer

mNSCLC

Bevacizumab

biosimilars

cost-efficiency

Bevacizumab-bvzr

savings

treatment access

budget-neutral